Newsfeeds - Spark Newswire

1 minute read

Jazz Pharma, Zymeworks Highlight 84% Overall Survival At 18 Months From Zanidatamab In Esophageal Cancer

Today, 1:10 PM

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and Zymeworks Inc (NASDAQ:ZYME) announced tolerability and efficacy results, including the first overall survival (OS) data, from…

JAZZ

1 minute read

HC Wainwright & Co. Maintains Neutral on Zymeworks BC, Lowers Price Target to $8

By Benzinga Newsdesk

Today, 1:10 PM

HC Wainwright & Co. analyst Robert Burns maintains Zymeworks BC (NYSE:ZYME) with a Neutral and lowers the price target from $10 to $8.

ZYME

1 minute read

Barclays Maintains Equal-Weight on Zymeworks BC, Raises Price Target to $9

By Benzinga Newsdesk

Today, 1:10 PM

Barclays analyst Gena Wang maintains Zymeworks BC (NYSE:ZYME) with a Equal-Weight and raises the price target from $7 to $9.

ZYME

2 minute read

Tesla, Amazon, Micron, Sintx, Zymeworks: Why These 5 Stocks Are Drawing Investors’ Attention Today

By Bhavik Nair

Today, 1:10 PM

U.S. markets soared on Wednesday as consumer confidence surged to an eight-month high in December following a drop in inflation and the labor market remaining strong. Twelve-month inflation expectations fell to their lowest level since Sept. 2021, at 6.7%, according to Reuters.

AMZN

1 minute read

Jazz Pharma Opts In, Advances Zanidatamab Partnership With Zymeworks

By Vandana Singh

Today, 1:10 PM

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) exercised its option to continue with its exclusive development and commercialization rights to Zymeworks Inc’s (NASDAQ:ZYME) zanidatamab in key…

JAZZ

4 minute read

Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

Today, 1:10 PM

Gainers Sintx Technologies, Inc. (NASDAQ: SINT) shares climbed 81.4% to $13.55 after the company was awarded Phase I contract for $150,000 from the Missile Defense Agency for electrochemical machining.

ADPT

1 minute read

Analyst Ratings

6 Analysts Have This to Say About Zymeworks BC

By Benzinga Insights

Today, 1:10 PM

Within the last quarter, Zymeworks BC (NYSE:ZYME) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

ZYME

1 minute read

Zymeworks Cancer Candidate Shows Objective Response Of 41% In Bile Duct Cancer

By Vandana Singh

Today, 1:10 PM

Zymeworks Inc (NASDAQ:ZYME) announced topline results from the pivotal Phase 2b HERIZON-BTC-01 trial investigating zanidatamab as monotherapy in patients with previously…

BGNE

2 minute read

Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium

By Benzinga Newsdesk

Today, 1:10 PM

Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the publication of an abstract highlighting new clinical data for zanidatamab, a

ZYME

1 minute read

HC Wainwright & Co. Maintains Neutral on Zymeworks BC, Raises Price Target to $10

By Benzinga Newsdesk

Today, 1:10 PM

HC Wainwright & Co. analyst Robert Burns maintains Zymeworks BC (NYSE:ZYME) with a Neutral and raises the price target from $8 to $10.

ZYME